vs

Side-by-side financial comparison of Axos Financial, Inc. (AX) and TG THERAPEUTICS, INC. (TGTX). Click either name above to swap in a different company.

Axos Financial, Inc. is the larger business by last-quarter revenue ($385.1M vs $192.6M, roughly 2.0× TG THERAPEUTICS, INC.). Axos Financial, Inc. runs the higher net margin — 33.3% vs 12.0%, a 21.4% gap on every dollar of revenue. On growth, TG THERAPEUTICS, INC. posted the faster year-over-year revenue change (78.0% vs 25.1%). Axos Financial, Inc. produced more free cash flow last quarter ($85.4M vs $19.6M). Over the past eight quarters, TG THERAPEUTICS, INC.'s revenue compounded faster (74.2% CAGR vs 14.3%).

Axos Financial is an American bank holding company based in Las Vegas, Nevada and is the parent of Axos Bank, a direct bank. It also offers registered investment adviser services and an electronic trading platform.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with B-cell malignancies, autoimmune diseases and neurodegenerative disorders. Its core operating markets are North America and Europe, with key product segments including targeted monoclonal antibodies and oral small molecule treatments.

AX vs TGTX — Head-to-Head

Bigger by revenue
AX
AX
2.0× larger
AX
$385.1M
$192.6M
TGTX
Growing faster (revenue YoY)
TGTX
TGTX
+52.9% gap
TGTX
78.0%
25.1%
AX
Higher net margin
AX
AX
21.4% more per $
AX
33.3%
12.0%
TGTX
More free cash flow
AX
AX
$65.8M more FCF
AX
$85.4M
$19.6M
TGTX
Faster 2-yr revenue CAGR
TGTX
TGTX
Annualised
TGTX
74.2%
14.3%
AX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
AX
AX
TGTX
TGTX
Revenue
$385.1M
$192.6M
Net Profit
$128.4M
$23.0M
Gross Margin
80.2%
Operating Margin
45.6%
26.2%
Net Margin
33.3%
12.0%
Revenue YoY
25.1%
78.0%
Net Profit YoY
22.6%
-1.3%
EPS (diluted)
$2.22
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AX
AX
TGTX
TGTX
Q4 25
$385.1M
$192.6M
Q3 25
$323.4M
$161.7M
Q2 25
$321.4M
$141.1M
Q1 25
$308.8M
$120.9M
Q4 24
$307.9M
$108.2M
Q3 24
$320.7M
$83.9M
Q2 24
$290.9M
$73.5M
Q1 24
$294.8M
$63.5M
Net Profit
AX
AX
TGTX
TGTX
Q4 25
$128.4M
$23.0M
Q3 25
$112.4M
$390.9M
Q2 25
$110.7M
$28.2M
Q1 25
$105.2M
$5.1M
Q4 24
$104.7M
$23.3M
Q3 24
$112.3M
$3.9M
Q2 24
$104.9M
$6.9M
Q1 24
$110.7M
$-10.7M
Gross Margin
AX
AX
TGTX
TGTX
Q4 25
80.2%
Q3 25
82.6%
Q2 25
86.6%
Q1 25
87.1%
Q4 24
85.8%
Q3 24
88.9%
Q2 24
88.7%
Q1 24
91.4%
Operating Margin
AX
AX
TGTX
TGTX
Q4 25
45.6%
26.2%
Q3 25
46.3%
18.2%
Q2 25
48.5%
24.7%
Q1 25
47.9%
7.1%
Q4 24
48.8%
27.7%
Q3 24
49.6%
14.8%
Q2 24
49.6%
12.0%
Q1 24
52.8%
-14.6%
Net Margin
AX
AX
TGTX
TGTX
Q4 25
33.3%
12.0%
Q3 25
34.7%
241.7%
Q2 25
34.4%
20.0%
Q1 25
34.1%
4.2%
Q4 24
34.0%
21.6%
Q3 24
35.0%
4.6%
Q2 24
36.0%
9.4%
Q1 24
37.6%
-16.9%
EPS (diluted)
AX
AX
TGTX
TGTX
Q4 25
$2.22
$0.14
Q3 25
$1.94
$2.43
Q2 25
$1.89
$0.17
Q1 25
$1.81
$0.03
Q4 24
$1.80
$0.16
Q3 24
$1.93
$0.02
Q2 24
$1.75
$0.04
Q1 24
$1.91
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AX
AX
TGTX
TGTX
Cash + ST InvestmentsLiquidity on hand
$1.0B
$142.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.9B
$648.0M
Total Assets
$28.2B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AX
AX
TGTX
TGTX
Q4 25
$1.0B
$142.0M
Q3 25
$2.6B
$131.6M
Q2 25
$1.9B
$251.9M
Q1 25
$2.0B
$276.2M
Q4 24
$2.4B
$311.0M
Q3 24
$2.6B
$341.0M
Q2 24
$2.0B
$217.3M
Q1 24
$2.1B
$209.8M
Total Debt
AX
AX
TGTX
TGTX
Q4 25
Q3 25
Q2 25
$312.7M
Q1 25
$377.4M
Q4 24
$358.7M
Q3 24
$313.5M
Q2 24
$325.7M
Q1 24
$330.4M
Stockholders' Equity
AX
AX
TGTX
TGTX
Q4 25
$2.9B
$648.0M
Q3 25
$2.8B
$607.2M
Q2 25
$2.7B
$276.4M
Q1 25
$2.6B
$237.3M
Q4 24
$2.5B
$222.4M
Q3 24
$2.4B
$192.2M
Q2 24
$2.3B
$177.6M
Q1 24
$2.2B
$160.1M
Total Assets
AX
AX
TGTX
TGTX
Q4 25
$28.2B
$1.1B
Q3 25
$27.4B
$1.0B
Q2 25
$24.8B
$702.6M
Q1 25
$24.0B
$656.7M
Q4 24
$23.7B
$577.7M
Q3 24
$23.6B
$586.0M
Q2 24
$22.9B
$401.2M
Q1 24
$22.6B
$373.3M
Debt / Equity
AX
AX
TGTX
TGTX
Q4 25
Q3 25
Q2 25
0.12×
Q1 25
0.14×
Q4 24
0.14×
Q3 24
0.13×
Q2 24
0.14×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AX
AX
TGTX
TGTX
Operating Cash FlowLast quarter
$104.1M
$19.7M
Free Cash FlowOCF − Capex
$85.4M
$19.6M
FCF MarginFCF / Revenue
22.2%
10.2%
Capex IntensityCapex / Revenue
4.9%
0.0%
Cash ConversionOCF / Net Profit
0.81×
0.85×
TTM Free Cash FlowTrailing 4 quarters
$695.9M
$-25.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AX
AX
TGTX
TGTX
Q4 25
$104.1M
$19.7M
Q3 25
$118.4M
$-23.2M
Q2 25
$490.3M
$7.4M
Q1 25
$73.7M
$-28.7M
Q4 24
$162.5M
$-25.6M
Q3 24
$70.8M
$-12.2M
Q2 24
$305.5M
$5.5M
Q1 24
$115.8M
$-8.2M
Free Cash Flow
AX
AX
TGTX
TGTX
Q4 25
$85.4M
$19.6M
Q3 25
$109.3M
$-23.2M
Q2 25
$436.1M
$7.4M
Q1 25
$65.1M
$-28.7M
Q4 24
$156.4M
$-25.7M
Q3 24
$53.0M
$-12.2M
Q2 24
$269.5M
Q1 24
$107.3M
FCF Margin
AX
AX
TGTX
TGTX
Q4 25
22.2%
10.2%
Q3 25
33.8%
-14.4%
Q2 25
135.7%
5.2%
Q1 25
21.1%
-23.8%
Q4 24
50.8%
-23.7%
Q3 24
16.5%
-14.6%
Q2 24
92.6%
Q1 24
36.4%
Capex Intensity
AX
AX
TGTX
TGTX
Q4 25
4.9%
0.0%
Q3 25
2.8%
0.0%
Q2 25
16.9%
0.0%
Q1 25
2.8%
0.0%
Q4 24
2.0%
0.0%
Q3 24
5.5%
0.0%
Q2 24
12.4%
0.0%
Q1 24
2.9%
0.0%
Cash Conversion
AX
AX
TGTX
TGTX
Q4 25
0.81×
0.85×
Q3 25
1.05×
-0.06×
Q2 25
4.43×
0.26×
Q1 25
0.70×
-5.67×
Q4 24
1.55×
-1.10×
Q3 24
0.63×
-3.15×
Q2 24
2.91×
0.80×
Q1 24
1.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

AX
AX

Segment breakdown not available.

TGTX
TGTX

Products$189.1M98%
License$3.5M2%

Related Comparisons